Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer Journal Article
| Authors: | Friedman, C. F.; Snyder Charen, A.; Zhou, Q.; Carducci, M. A.; Buckley De Meritens, A.; Corr, B. R.; Fu, S.; Hollmann, T. J.; Iasonos, A.; Konner, J. A.; Konstantinopoulos, P. A.; Modesitt, S. C.; Sharon, E.; Aghajanian, C.; Zamarin, D. |
| Article Title: | Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer |
| Abstract: | BACKGROUND: There are limited treatment options for patients with metastatic or recurrent cervical cancer. Platinum-based chemotherapy plus the anti-vascular endothelial growth factor antibody bevacizumab remains the mainstay of advanced treatment. Pembrolizumab is Food and Drug Agency approved for programmed death ligand 1 (PD-L1) positive cervical cancer with a modest response rate. This is the first study to report the efficacy and safety of the PD-L1 antibody atezolizumab in combination with bevacizumab in advanced cervical cancer. METHODS: We report the results from a phase II, open-label, multicenter study (NCT02921269). Patients with advanced cervical cancer were treated with bevacizumab 15 mg/kg intravenous every 3 weeks and atezolizumab 1200 mg intravenous every 3 weeks. The primary objective was to measure the objective response rate (ORR). Secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: In the total evaluable population (n=10), zero patients achieved an objective response as assessed by Response Evaluation Criteria In Solid Tumors (RECIST) V.1.1, resulting in a confirmed ORR of 0%. Of note, there were two patients who achieved an unconfirmed PR. The DCR by RECIST V.1.1 was 60% (0% complete response, 0% partial response, 60% stable disease). Median PFS was 2.9 months (95% CI, 1.8 to 6) and median OS was 8.9 months (95% CI, 3.4 to 21.9). Safety results were generally consistent with the known safety profile of both drugs, notably with two high-grade neurologic events. CONCLUSIONS: The combination of bevacizumab and atezolizumab did not meet the predefined efficacy endpoint, as addition of bevacizumab to PD-L1 blockade did not appear to enhance the ORR in cervical cancer. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. |
| Keywords: | drug therapy; combination; tumor biomarkers; female; programmed cell death 1 receptor; genital neoplasms |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 8 |
| Issue: | 2 |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2020-07-01 |
| Start Page: | e001126 |
| Language: | English |
| DOI: | 10.1136/jitc-2020-001126 |
| PUBMED: | 33004542 |
| PROVIDER: | scopus |
| PMCID: | PMC7534695 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 November 2020 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work